# Glaukos Corporation (GKOS) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $177.47, market value $10.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Glaukos Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 17.1×**. Each dollar of revenue is priced at 17.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 15.3×**. The shares trade at 15.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -0.1%** (5-yr avg -1.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 60.7%**. Glaukos Corporation keeps 60.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -31.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -37.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -28.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -27.0%**. Return on all capital, debt included, is -27.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -21.0%**. Each dollar of assets produces -21.0% of profit.

## Growth
- **Revenue growth (1 yr): 32.3%** (3-yr 21.5%/yr, 5-yr 17.7%/yr). Revenue grew 32.3% over the last year, against 17.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -18.4%**. Earnings per share fell 18.4%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.6×**. It would take 0.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 4.69** (quick 4.69). Current assets cover the next year's liabilities 4.69 times.
- **Altman Z-score: 27.82**. A Z-score of 27.82 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Glaukos Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Glaukos Corporation; the consensus is strong_buy, with an average price target of $197.15 (+11% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 96.9%** (YTD 57.2%, 3-mo 42.0%). The shares are up 96.9% over twelve months including dividends.
- **From 52-week high: -7.4%** (142.6% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.86** (volatility 52%). Beta of 0.86 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GKOS · Page: https://foliofundamentals.com/stocks/gkos

Not investment advice.